169 related articles for article (PubMed ID: 33076217)
21. Endothelial Dysfunction and Advanced Glycation End Products in Patients with Newly Diagnosed Versus Established Diabetes: From the CORDIOPREV Study.
de la Cruz-Ares S; Cardelo MP; Gutiérrez-Mariscal FM; Torres-Peña JD; García-Rios A; Katsiki N; Malagón MM; López-Miranda J; Pérez-Martínez P; Yubero-Serrano EM
Nutrients; 2020 Jan; 12(1):. PubMed ID: 31963378
[TBL] [Abstract][Full Text] [Related]
22. Association of major dietary patterns with advanced glycation end products and high-sensitivity C-reactive protein in people with type 1 diabetes mellitus.
Ebrahimi Z; Shojaeian Z; Amiri F; Esmaillzadeh A; Sadeghi O; Esteghamati A; Jahed SA; Sedaghat S
Nutr J; 2023 Jul; 22(1):37. PubMed ID: 37496018
[TBL] [Abstract][Full Text] [Related]
23. Is dietary intake of advanced glycation end products associated with mortality among adults with diabetes?
Koyama AK; Pavkov ME; Wu Y; Siegel KR
Nutr Metab Cardiovasc Dis; 2022 Jun; 32(6):1402-1409. PubMed ID: 35282981
[TBL] [Abstract][Full Text] [Related]
24. Dietary Advanced Glycation End Products and Risk Factors for Chronic Disease: A Systematic Review of Randomised Controlled Trials.
Clarke RE; Dordevic AL; Tan SM; Ryan L; Coughlan MT
Nutrients; 2016 Mar; 8(3):125. PubMed ID: 26938557
[TBL] [Abstract][Full Text] [Related]
25. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1.
Uribarri J; Cai W; Ramdas M; Goodman S; Pyzik R; Chen X; Zhu L; Striker GE; Vlassara H
Diabetes Care; 2011 Jul; 34(7):1610-6. PubMed ID: 21709297
[TBL] [Abstract][Full Text] [Related]
26. Fluorescent serum and urinary advanced glycoxidation end-products in non- diabetic subjects.
Maza MP; Bravo A; Leiva L; Gattás V; Petermann M; Garrido F; Bunout D; Hirsch S; Barrera G; Fernández M
Biol Res; 2007; 40(2):203-12. PubMed ID: 18064357
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of a 6-month pilot randomised controlled trial of resistance training on cognition and brain health in Canadian older adults at-risk for diabetes: study protocol.
Furlano JA; Nagamatsu LS
BMJ Open; 2019 Oct; 9(10):e032047. PubMed ID: 31585978
[TBL] [Abstract][Full Text] [Related]
28. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes.
Kopytek M; Ząbczyk M; Mazur P; Undas A; Natorska J
Cardiovasc Diabetol; 2020 Jun; 19(1):92. PubMed ID: 32552684
[TBL] [Abstract][Full Text] [Related]
29. Dietary Advanced Glycation End Products Consumption as a Direct Modulator of Insulin Sensitivity in Overweight Humans: A Study Protocol for a Double-Blind, Randomized, Two Period Cross-Over Trial.
de Courten B; de Courten MP; Schalkwijk CG; Walker KZ; Forbes J
JMIR Res Protoc; 2015 Jul; 4(3):e93. PubMed ID: 26223897
[TBL] [Abstract][Full Text] [Related]
30. Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review.
Kellow NJ; Savige GS
Eur J Clin Nutr; 2013 Mar; 67(3):239-48. PubMed ID: 23361161
[TBL] [Abstract][Full Text] [Related]
31. The relationship between dietary advanced glycation end products and indicators of diabetes severity in Mexicans and non-Hispanic whites: a pilot study.
Luevano-Contreras C; Garay-Sevilla ME; Preciado-Puga M; Chapman-Novakofski KM
Int J Food Sci Nutr; 2013 Feb; 64(1):16-20. PubMed ID: 22779780
[TBL] [Abstract][Full Text] [Related]
32. Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial.
Vlassara H; Cai W; Tripp E; Pyzik R; Yee K; Goldberg L; Tansman L; Chen X; Mani V; Fayad ZA; Nadkarni GN; Striker GE; He JC; Uribarri J
Diabetologia; 2016 Oct; 59(10):2181-92. PubMed ID: 27468708
[TBL] [Abstract][Full Text] [Related]
33. Effect of reducing dietary advanced glycation end products on obesity-associated complications: a systematic review.
Ribeiro PVM; Tavares JF; Costa MAC; Mattar JB; Alfenas RCG
Nutr Rev; 2019 Oct; 77(10):725-734. PubMed ID: 31228247
[TBL] [Abstract][Full Text] [Related]
34. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1.
Vlassara H; Cai W; Goodman S; Pyzik R; Yong A; Chen X; Zhu L; Neade T; Beeri M; Silverman JM; Ferrucci L; Tansman L; Striker GE; Uribarri J
J Clin Endocrinol Metab; 2009 Nov; 94(11):4483-91. PubMed ID: 19820033
[TBL] [Abstract][Full Text] [Related]
35. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients.
Uribarri J; Peppa M; Cai W; Goldberg T; Lu M; Baliga S; Vassalotti JA; Vlassara H
Am J Kidney Dis; 2003 Sep; 42(3):532-8. PubMed ID: 12955681
[TBL] [Abstract][Full Text] [Related]
36. Advanced glycation end products and endothelial dysfunction in type 2 diabetes.
Tan KC; Chow WS; Ai VH; Metz C; Bucala R; Lam KS
Diabetes Care; 2002 Jun; 25(6):1055-9. PubMed ID: 12032114
[TBL] [Abstract][Full Text] [Related]
37. Circulating Concentrations of Advanced Glycation end Products, its Association With the Development of Diabetes Mellitus.
Jiménez IU; Díaz-Díaz E; Castro JS; Ramos JP; León MC; Alvarado Ríos JA; Auriostigue Bautista JC; Correa-Rotter R; Aguilar Salinas CA; Larrea F
Arch Med Res; 2017 May; 48(4):360-369. PubMed ID: 29157674
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.
Kilhovd BK; Berg TJ; Birkeland KI; Thorsby P; Hanssen KF
Diabetes Care; 1999 Sep; 22(9):1543-8. PubMed ID: 10480523
[TBL] [Abstract][Full Text] [Related]
39. A quick, simple method for detecting circulating fluorescent advanced glycation end-products: Correlation with in vitro and in vivo non-enzymatic glycation.
Villa M; Parravano M; Micheli A; Gaddini L; Matteucci A; Mallozzi C; Facchiano F; Malchiodi-Albedi F; Pricci F
Metabolism; 2017 Jun; 71():64-69. PubMed ID: 28521879
[TBL] [Abstract][Full Text] [Related]
40. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.
Galler A; Müller G; Schinzel R; Kratzsch J; Kiess W; Münch G
Diabetes Care; 2003 Sep; 26(9):2609-15. PubMed ID: 12941727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
